These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20374075)

  • 1. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
    Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
    Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of quality-of-life assessment in the management of patients with multiple sclerosis. Recommendations from the Middle East MS Advisory Group.
    Al-Tahan AM; Al-Jumah MA; Bohlega SM; Al-Shammari SN; Al-Sharoqi IA; Dahdaleh MP; Hosny HM; Yamout BI
    Neurosciences (Riyadh); 2011 Apr; 16(2):109-13. PubMed ID: 21427658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
    Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
    Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Lugaresi A
    Expert Opin Drug Deliv; 2009 Sep; 6(9):995-1002. PubMed ID: 19637982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R; Kinsella K; Duggan M; Jordan S; Hutchinson M; Tubridy N
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment optimisation in multiple sclerosis.
    Zaffaroni M
    Neurol Sci; 2005 Dec; 26 Suppl 4():S187-92. PubMed ID: 16388356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disease-modifying treatment of MS--progress with complications].
    Fagius J
    Lakartidningen; 2003 Mar; 100(13):1164, 1167-8. PubMed ID: 12705166
    [No Abstract]   [Full Text] [Related]  

  • 10. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.
    Lugaresi A; Rottoli MR; Patti F
    Expert Rev Neurother; 2014 Sep; 14(9):1029-42. PubMed ID: 25109614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical surveillance of patients with multiple sclerosis].
    Cazzato G; Zorzon M
    Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
    Velligan DI; Weiden PJ; Sajatovic M; Scott J; Carpenter D; Ross R; Docherty JP;
    J Clin Psychiatry; 2009; 70 Suppl 4():1-46; quiz 47-8. PubMed ID: 19686636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gap between effect of drugs and effectiveness of treatments.
    Sorensen PS
    J Neurol Sci; 2007 Aug; 259(1-2):128-32. PubMed ID: 17362994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
    Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract]   [Full Text] [Related]  

  • 17. Betaseron: a breakthrough treatment for multiple sclerosis.
    Morrison W; Nelson J
    Can Nurse; 1996 Oct; 92(9):38-41. PubMed ID: 9118060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.
    Putzki N; Katsarava Z; Vago S; Diener HC; Limmroth V
    Eur Neurol; 2008; 59(3-4):136-42. PubMed ID: 18057900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.